Table 3.
Objective response rates in selected subgroups (regorafenib = 80 mg)
| Subgroup | No. of patients | Objective response |
|---|---|---|
| All patients | 33 (100%) | 5 (15.2%) |
| Liver metastases | ||
| Yes | 23 (69.7%) | 2 (8.7%) |
| No | 10 (30.3%) | 3 (30.0%) |
| Lung metastases | ||
| Yes | 21 (63.6%) | 3 (14.3%) |
| No | 12 (36.4%) | 2 (16.7%) |
| Primary site | ||
| Right colon | 11 (33.3%) | 2 (18.2%) |
| Left colon/rectum | 22 (66.7%) | 3 (13.6%) |
| MSI/MMR status | ||
| MSS/ pMMR | 32 (97.0%) | 5 (15.6%) |
| MSI-L | 1 (3.0%) | 0 (0%) |
| RAS/BRAF status | ||
| RAS and BRAFV600E wild type | 13 (39.4%) | 2 (15.4%) |
| RAS mutant | 18 (54.5%) | 2 (11.1%) |
| BRAFV600E mutant | 2 (6.1%) | 1 (50.0%) |
| Prior anti-VEGF inhibitors | ||
| Yes | 22 (66.7%) | 4 (18.2%) |
| No | 11 (33.3%) | 1 (9.1%) |
| Prior anti-EGFR inhibitors | ||
| Yes | 7 (21.2%) | 2 (28.6%) |
| No | 26 (78.8%) | 3 (11.5%) |
| Current treatment line | ||
| 3 | 23 (69.7%) | 1 (4.3%) |
| ≥4 | 10 (30.3%) | 4 (40.0%) |
| ECOG PS score | ||
| 0 | 2 (6.1%) | 0 (0%) |
| 1 | 31 (93.9%) | 5 (16.1%) |
| BMI | ||
| <median | 16 (48.5%) | 3 (18.8%) |
| ≥median | 17 (51.5%) | 2 (11.8%) |
| Lung-only metastases | ||
| Yes | 3 (9.1%) | 3 (100%) |
| No | 30 (90.9%) | 2 (6.7%) |
| Liver-only metastases | ||
| Yes | 4 (12.1%) | 0 (0%) |
| No | 29 (87.9%) | 5 (17.2%) |
See also Figure S1. ECOG PS, Eastern Cooperative Oncology Group performance status